AltaRex Licenses U.S. Issued Patents

AltaRex Corp. has obtained an exclusive worldwide license for a family of four U.S issued patents and foreign counterparts from the Alberta Research Council, Inc. (ARC) in Edmonton, Alberta.

These additions to the Company’s intellectual property portfolio provide AltaRex with a strong foundation for developing novel treatments in the area of autoimmune/inflammatory disease, such as multiple sclerosis, Crohn’s disease, and allergy/asthma.

The Company’s current proprietary technology applies to a number of disease areas (cancer, infectious disease and autoimmune/inflammatory disease), with current clinical development focused on cancer.

“We believe that we have a broad technology platform, and anticipate generating near term return from our antibodies to treat cancer.

We are prudently extending our intellectual property now, with a future focus on promising and synergistic therapeutic areas,” commented Richard E. Bagley, President and CEO of AltaRex Corp.

The family of U.S. issued patents obtained by AltaRex from the ARC includes three method patents titled ‘Anti Inflammatory Tolerogenic and Immunoinhibiting Properties of Carbohydrate Binding Peptides’ and one composition patent titled ‘Lectin Derived Carbohydrate Binding Peptides’. These patents are relevant to the Company’s established proprietary expertise in the use of binding agents, specifically antibodies, to alter patients’ immune system responses in a therapeutically beneficial manner.

The Alberta Research Council develops and commercialises technologies to give customers a competitive advantage.

The corporation performs applied research and development on a contract or fee basis, and co-ventures with others to develop new technologies, deriving a return on investment from the commercialisation of new products and processes.

ARC also conducts applied research projects for the public good and to support provincial science and technology needs and strategies.

AltaRex Corp. is primarily focused on the research, development and commercialisation of antigen-targeted antibody-based cancer therapies, utilizing monoclonal antibodies as immunotherapeutic agents for the treatment of certain late-stage cancers.

Purchasing Dragon Pharma of Top Quality

Trenbolone 100

Injectable Anabolic Steroid
Active Component: Trenbolone Acetate
Branded by: Dragon Pharma
Pack: 1 X 10 ml (100 mg/ml)

Sustanon 350 - Cheap Price

Administration: Injection
Primary Ingredient: Testosterone Blend
Made by: Dragon Pharmaceutical
Pack: 20 x 10 mL vial (350 mg/mL)
Price: 20 x $40.00

Winstrol Depot

Injectable Anabolic Steroid
Principal Chemical Name: Stanozolol
Made by: Dragon Pharma
Package: 1 X 10 ml (50 mg/ml)

TriTren 150 - Bulk Price

Administration: Injection
Main Chemical Name: Tri Trenbolone
Producer: Dragon Pharma LLC
Amount: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $72.00


Beta-2 Agonist, Bronchodilator
Primary Component: Clenbuterol Hydrochloride
Branded by: Dragon Pharmaceutical
Pack: 1 X 100 pills (40 mcg/pill)

Masteron 100 - Bulk Price

Administration: Injection
Primary Component: Drostanolone Di-Propionate
Branded by: Dragon Pharma LLC
Pack: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $49.00

Winstrol Tabs

Oral Steroid for Muscle Growth
Basal Ingredient: Stanozolol
Produced by: Dragon Pharmaceutical
100 tablets (50 mg/pill)

Parabolan 100

Injectable Steroid for Muscle Growth
Main Constituent: Trenbolone Hexahydrobenzylcarbonate
Branded by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (100 mg/mL)

Cut Mix 150

Injectable Steroid for Muscle Growth
Mix of: Testosterone Propionate,
Drostanolone Propionate, Trenbolone Acetate
Manufacturer: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (150 mg/mL)

Masteron 200

Prime Ingredient: Drostanolone Enanthate
Manufacturer: Dragon Pharmaceuticals
Unit: 10 mL vial (200 mg/mL)

Trenbolone 100

Base Component: Trenbolone Acetate
Produced by: Dragon Pharmaceuticals
Unit: 10 mL vial (100 mg/mL)

Primobolan 200

Principal Ingredient: Methenolone Enanthate
Produced by: Dragon Pharmaceutical
Pack: 10 mL vial (200 mg/mL)